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Abstract
Rationale: Studies of excised lungs show that signiﬁcant airway
attrition in the “quiet” zone occurs early in chronic obstructive
pulmonary disease (COPD).
Objectives: To determine if the total number of airways quantiﬁed
in vivo using computed tomography (CT) reﬂects early airway-
related disease changes and is associated with lung function decline
independent of emphysema in COPD.
Methods: Participants in the multicenter, population-based,
longitudinal CanCOLD (Canadian Chronic Obstructive Lung Disease)
study underwent inspiratory/expiratory CT at visit 1; spirometry was
performed at four visits over 6 years. Emphysema was quantiﬁed as
the CT inspiratory low-attenuation areas below2950 Hounsﬁeld units.
CT total airway count (TAC) was measured as well as airway inner
diameter and wall area using anatomically equivalent airways.
Measurements and Main Results: Participants included never-
smokers (n= 286), smokers with normal spirometry at risk for COPD
(n=298), Global Initiative for Chronic Obstructive Lung Disease (GOLD) I
COPD (n= 361), and GOLD II COPD (n= 239). TAC was signiﬁcantly
reduced by 19% in both GOLD I and GOLD II compared with never-
smokers (P, 0.0001)andby17%inbothGOLDIandGOLDIIcompared
with at-risk participants (P, 0.0001) after adjusting for low-attenuation
areas below2950 Hounsﬁeld units. Further analysis revealed parent
airways with missing daughter branches had reduced inner diameters
(P, 0.0001) and thinner walls (P, 0.0001) compared with those
without missing daughter branches. Among all CT measures, TAC had
the greatest inﬂuence on FEV1 (P, 0.0001), FEV1/FVC (P, 0.0001),
andbronchodilator responsiveness (P, 0.0001).TACwas independently
associatedwith lungfunctiondecline (FEV1,P= 0.02;FEV1/FVC,P= 0.01).
Conclusions: TAC may reﬂect the airway-related disease changes
that accumulate in the “quiet” zone in early/mild COPD, indicating
that TAC acquired with commercially available software across
various CT platforms may be a biomarker to predict accelerated
COPD progression.
Keywords: computed tomography; chronic obstructive
pulmonary disease; chronic obstructive pulmonary disease
progression; emphysema; small airway disease
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Airﬂow limitation measured during a forced
expiratory maneuver is the physiologic
hallmark of chronic obstructive pulmonary
disease (COPD) (1). Although the site of
this obstruction has been localized to the
small conducting airways less than 2 mm in
diameter (2), much remains to be learned
about the pathology responsible for this
obstruction to airﬂow. To date, the most
detailed studies of the structural features
of this obstruction to ﬂow have been
performed using micro computed
tomography (micro-CT) images of samples
removed from excised lungs donated by
patients with very severe COPD treated
by lung transplantation (3). These
investigations show there is massive
destruction of the terminal bronchioles
before emphysematous lesions become
visible at the approximate 15-mm spatial
resolution provided by micro-CT, and long
before they are large enough to be visible at
the approximate 1-mm spatial resolution
provided by multidetector CT.
Advanced CT image processing now
makes it possible to segment the airway tree
from the trachea to the smaller airways at
the resolution of the CT systems, airways
approximately 2mm in diameter. Therefore,
the purpose of this study was to use
commercially available software (VIDA
Diagnostics, Inc.) to segment the airway tree
and count the total number of CT airways in
CanCOLD (Canadian Chronic Obstructive
Lung Disease) participants. Importantly,
CanCOLD is a multicenter, population-
based study (4) and therefore participants
represent mild, more ambulant
presentations of COPD. We hypothesized
that the narrowing, obstruction, and/or
destruction of the terminal bronchioles that
occur before emphysema development (3)
is also reﬂected in the proximal airways
and can be quantiﬁed using the CT total
airway count (TAC). Furthermore, we
hypothesized that TAC is signiﬁcantly
reduced in mild COPD compared with
never-smokers, and is signiﬁcantly
associated with lung-function decline over
time.
Methods
Study Participants
Written informed consent was obtained
from participants in the multicenter
CanCOLD study, which was approved by
the institutional review boards at each study
site. Brieﬂy, CanCOLD is a prospective,
multicenter (nine sites in six Canadian
provinces), longitudinal study investigating
individuals greater than 40 years of age that
were randomly selected from the general
population (4). COPD was deﬁned
spirometrically according to Global
Initiative for Chronic Obstructive Lung
Disease (GOLD) criteria (5). A ﬂowchart
detailing how participants were selected for
analysis is shown in Figure 1. For the
participants evaluated in this study, the
mean time between visit 0 and visits 1, 2,
and 3 was (mean6 SD) 2.56 1.7 years,
4.46 1.7 years, and 5.96 1.8 years,
respectively.
Pulmonary Function Tests
Spirometry was performed for measurement
of the FEV1 and FVC before and 15
minutes following inhalation of 200 mg
albuterol according to American Thoracic
Society guidelines (6–8). Bronchodilator
response (BDR) was deﬁned as the percent
change in FEV1 (L) after bronchodilator
inhalation [(FEV1 post-BD 2 FEV1
pre-BD)/FEV1 pre-BD]3 100. Whole-body
plethysmography was performed for
measurement of the residual volume/total
lung capacity (RV/TLC) ratio and DLCO.
CT Image Acquisition
CT images were acquired at each of the
nine sites using CT systems of various
makes and models with the participant
supine at suspended full-inspiration and
full-expiration from apex to base of the
lung as previously described (4). The CT
parameters for image acquisition are as
follows: 100 kVp, 50 mAs, 0.5-second
gantry rotation, pitch of 1.375, and 1.0- or
1.25-mm slice thickness, contiguous slices.
The standard or soft tissue reconstruction
kernel was used for quantitative analysis.
CT Image Analysis
CT images were evaluated using the Apollo
2.0 software package (VIDA Diagnostics,
Inc.) and the VIDA Diagnostics, Inc.,
clinical image analysis service, that is
ISO13485 certiﬁed for quality control.
Brieﬂy, to generate the CT airway
measurements, the CT airway tree was ﬁrst
automatically segmented and the airways
were automatically labeled from the trachea
to the subsegmental bronchi. Airway
segmentation and labeling were visually
veriﬁed by a highly trained analyst and
edited if required; a second analyst
then performed peer review of the
segmentation and labeling for quality
control. A detailed description of VIDA
Diagnostics, Inc., clinical image analysis
service airway segmentation workﬂow is
provided in the online supplement. The high
reproducibility of airway measurements
generated by VIDA Diagnostics, Inc.,
clinical image analysis services has been
previously reported (9).
The TAC measurements were obtained
by summing all airway segments from the
segmented airway tree. Airway counts were
At a Glance Commentary
Scientiﬁc Knowledge on the
Subject: There is evidence that
massive destruction of terminal
bronchioles is well established before
the appearance of emphysematous
destruction in chronic obstructive
pulmonary disease (COPD). However,
it is unknownwhether this reduction in
small airway number is reﬂected in the
more central airways evaluated in vivo
using computed tomography (CT)
in individuals with mild COPD
independent of emphysema. To
our knowledge, there have been no
studies investigating CT airway
count and the relationship with lung
function decline in participants with
early/mild COPD.
What This Study Adds to the
Field: In a population-based sample of
participants we demonstrate that CT
airway count is signiﬁcantly reduced
in mild COPD independent of
emphysema, that missing airways
are spatially related to parent
airway wall thinning and luminal
narrowing/tapering, and that reduced
CT airway count is signiﬁcantly and
independently associated with rapid
decline in lung function over time.
These ﬁndings indicate that early
airway-related changes can be assessed
in vivo using CT acquired in at-risk
individuals at multiple sites and across
various CT platforms, highlighting the
feasibility and applicability of these
ﬁndings. Most importantly, these
ﬁndings also suggest that early
intervention may be required for
optimal disease modiﬁcation.
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also generated by airway generation
starting at the trachea (generation 0) to
generation 10 and by airway diameter.
Only anatomically equivalent segmental,
subsegmental, and sub-subsegmental
airways for ﬁve predetermined airway paths
(RB1, RB4, RB10, LB1, and LB10) were
used to generate airway inner lumen area,
lumen diameter, and airway wall area (9).
Subsegmental airway inner lumen diameter
tapering was deﬁned as the ratio of the
airway lumen diameter measurements at
points 30% and 70% along the length of the
airway segment between the parent branch
point (0%) and the daughter branch point
(100%). Pi10 was deﬁned as the wall
thickness of a theoretical airway with a
lumen perimeter of 10 mm (10) and was
calculated using anatomically equivalent
airways.
Emphysema was quantiﬁed on
full-inspiration CT images using the low-
attenuation areas of the lung below 2950
Hounsﬁeld units (HU) (LAA950) (11–13).
Gas trapping was also quantiﬁed using
full-expiration CT images as the low-
attenuation area of the lung below 2856
HU (LAA856) (14, 15). The presence or
absence of bronchiectasis (binary variable)
was visually scored by radiologists
blinded to participants’ clinical
characteristics. In a subgroup analysis
of 494 participants that were randomly
selected for a separate study (n = 140
never-smokers, n = 103 at-risk, n = 149
GOLD I, n = 102 GOLD II), CT parametric
response mapping (PRM) functional
small airway disease (fSAD) and
emphysema measurements were generated
by registering images acquired at
full-inspiration to images acquired at
full-expiration and applying established
thresholds, as previously described (16).
Statistical Analysis
All statistical analysis was performed using
SAS version 9.4 software. A one-way
ANOVA with a Tukey test for multiple
comparison correction was performed
for statistical comparison between
never-smokers, at-risk, GOLD I, and
GOLD II COPD groups for participant
demographic, pulmonary function, and CT
measurements. For categorical variables, a
Fisher exact test was used. An analysis
of covariance was used for statistical
comparison of TAC measurements between
all groups (never-smoker, at-risk, GOLD I,
and GOLD II) adjusted by confounding
COLD / Prevalence
Cohort 
Study Design
Visit 0
Demographics
Smoking History
Spirometry
Demographics
Smoking History
Spirometry
Demographics
Smoking History
Spirometry
Plethysmography
Questionnaires
CT Imaging
Demographics
Smoking History
Spirometry
Plethysmography
Questionnaires
CT Imaging
Visit 1 Visit 2 Visit 3
CanCOLD / Longitudinal
Cohort 
A
Participant Selection
Eligible Participants
n=339, never-Smokers
n=340, at risk
n=90, PRISm
n=398, GOLD I
n=273, GOLD II
n=39 GOLD III+
Baseline CanCOLD  Cohort Total n=1,532
Eligible Participants n=1,350
Participants Selected for Analysis, n=1,184
Classification Information Missing
n=10, no smoking status
n=43, no spirometry
Selection Criteria Not Met
n=90, PRISm
n=39, GOLD III+
No CT Available/Analysis Failure n=166
B
Longitudinal Data
Visit 0 Visit 1 Visit 2 Visit 3
n=638n=788n=1,184 n=1,184
C
Figure 1. Subject selection flowchart. (A) Participants included in the COLD (Chronic Obstructive
Lung Disease) prevalence study were selected to participate in the longitudinal CanCOLD (Canadian
Chronic Obstructive Lung Disease) study as previously described (4). (B) The baseline CanCOLD
cohort included n = 1,532 participants. Participants with no classifying information, namely no
information related to smoking status (n = 10) and spirometry (n = 43), were excluded. For those
participants classified, participants with preserved FEV1/FVC ratio but decreased FEV1, also known
as preserved ratio but impaired spirometry (n = 90), were excluded. Given the paucity of GOLD III1
participants (n = 39), they were also excluded from our analysis. Finally, participants for whom
computed tomography images could not be analyzed for any reason were excluded (n = 166). The
final number of n = 1,184 participants were included in the analysis. (C) For the participants selected
for the analysis, spirometry measurements were obtained from the original COLD study and from
the ongoing longitudinal CanCOLD study to evaluate the lung function trajectory. CT = computed
tomography; GOLD =Global Initiative for Chronic Obstructive Lung Disease; PRISm= preserved ratio
but impaired spirometry.
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variables (age; sex; race; pack-years;
smoking status; body mass index [BMI];
history of asthma; history of tuberculosis;
history of heart disease, systemic
hypertension, or diabetes mellitus; history of
bronchiectasis; FEV1% predicted; CT air
volume; and CT scanner model); a separate
analysis of covariance was performed that
was also adjusted by LAA950 in addition to
other confounding variables.
For comparison of airway inner
diameter, airway wall area, and inner
diameter tapering measurements for all
subsegmental airways in participants with
daughter branches missing or not missing,
we used a Mann-Whitney t test. We
determined if subsegmental parent airways
were missing their sub-subsegmental
daughter branches using the output ﬁle
exported by the Apollo 2.0 software; all
airway segments were assigned a unique
identiﬁer that linked each parent airway to
the corresponding daughter branches. We
conservatively deﬁned participants with
missing daughter branches if parent
airways with at least one of their daughter
branches was missing. A multivariable
logistic regression analysis was also used to
determine if parent airway lumen diameter,
airway wall area, and inner diameter
tapering measurements remained
signiﬁcantly associated with daughter
branches missing or not missing (binary
variable) after adjusting for potential
confounding variables.
In the subset of participants with
inspiration-to-expiration PRM
measurements, a multivariable linear
regression analysis was used to determine
the associations for TAC using all CT
measurements (PRM-fSAD, PRM-
emphysema, Pi10, lumen area) adjusted
by confounding variables. A multivariable
regression analysis was used to determine
variables with signiﬁcant associations
with FEV1, FEV1/FVC, RV/TLC, and BDR
using all CT measurements adjusted by
confounding variables. We reported the
standardized b coefﬁcients, that are
estimates expressed in units of standard
deviation so that the independent variables
could be compared based on their relative
effect on the dependent variable in terms of
standard deviation change. A linear mixed
effects model using the residual (restricted)
maximum likelihood estimation method for
the covariance parameters was performed
for longitudinal FEV1 and FEV1/FVC
change; baseline variables included age, sex,
BMI, race, smoking status, FEV1, TAC, and
LAA950; interaction terms for baseline
TAC, LAA950, and FEV1 with time were
included; time alone was also included in
the model.
Results
Participant Demographics,
Pulmonary Function, and Imaging
Measurements
The participant demographics, pulmonary
function, and imaging measurements for all
1,184 participants evaluated (n = 286 never-
smokers without airﬂow limitation, n = 298
at-risk, n = 361 GOLD I, n = 239 GOLD II
COPD) are provided in Table 1. GOLD I
participants were signiﬁcantly older than
participants in the at-risk group (P = 0.03)
and had fewer females than the never-
smoker (P = 0.0007) and at-risk (P = 0.01)
groups. There were no other differences
between the groups for age, sex, race, or
BMI. Pack-years smoking and other
pulmonary function measurements
worsened with increasing disease severity
as shown in Table 1.
The imaging measurements showed
LAA856 and LAA950 were signiﬁcantly
elevated and TAC and airway inner area
were signiﬁcantly reduced in GOLD I and
II compared with the never-smoker and
at-risk groups (P, 0.05); TAC and airway
inner area were signiﬁcantly reduced in
GOLD II compared with GOLD I COPD
(P, 0.05). For the subset of participants
with PRM measurements, PRM-fSAD was
signiﬁcantly elevated in GOLD II compared
with never-smokers and at-risk participants
(P, 0.05). PRM-emphysema was
signiﬁcantly elevated in GOLD II compared
with the never-smokers, at-risk, and GOLD I
participants (P. 0.05). There were no
differences between the never-smokers and
at-risk participants for any of the imaging
measurements (P. 0.05).
What Sizes of Airways Are Reduced
with Increasing COPD Disease
Severity?
In Figure 2A, three-dimensional CT airway
tree reconstructions visually demonstrate
the reduction in the total number of
airways with increasing disease severity as
shown quantitatively in Figures 2B and 2C.
The TAC was signiﬁcantly reduced for
airway generations more distal to the
segmental airways (generation 3) for GOLD I
and GOLD II compared with never-
smokers and at-risk (P, 0.0001); and
GOLD II compared with GOLD I COPD
(P, 0.0001). Figure 2C shows that the
TAC was not signiﬁcantly different
between the groups for airways less than
2.00 mm and 2.00–2.49 mm (P. 0.05),
but was signiﬁcantly reduced for all other
airway diameter sizes for GOLD I and
GOLD II COPD compared with never-
smokers and at-risk (P, 0.0001) and for
GOLD II compared with GOLD I COPD
(P, 0.0001). The distribution of CT airways
by generation and by airway diameter is also
shown in Tables E2 and E3 in the online
supplement.
Was TAC Reduction with Increasing
COPD Disease Severity Independent
of Emphysema and Related to Airway
Narrowing/Tapering?
Figure 3 shows that TAC was signiﬁcantly
reduced in GOLD I and GOLD II
compared with never-smokers (P, 0.0001)
and at-risk (P, 0.0001), after adjusting
for confounding variables; TAC was not
signiﬁcantly different between GOLD I and
GOLD II (P. 0.05). Importantly, these
differences persisted after adjusting for
LAA950 whereby TAC was signiﬁcantly
reduced by 19% in both GOLD I and
GOLD II compared with never-smokers
(P, 0.0001), and by 17% in both GOLD I
and GOLD II compared with at-risk
(P, 0.0001) participants.
The three-dimensional reconstructions
of the segmented airway tree along with
the two-dimensional airway path from the
trachea to the sub-subsegmental daughter
branch for RB1 for two representative
participants show that the parent airway
diameter was signiﬁcantly decreased in the
participant with a missing daughter branch
(Figure 4B) compared with the participant
without a missing daughter branch
(Figure 4A). In all participants, Figure 4C
shows that those with missing daughter
branches had parent airways with
signiﬁcantly narrowed lumen diameters
(P, 0.0001), reduced airway wall area
(P, 0.0001), and greater lumen diameter
tapering (P, 0.0001) than those
participants with no missing daughter
branches. Moreover, for parent airways,
the decrease airway lumen diameter
(P, 0.0001), decrease in airway wall area
(P, 0.0001), and increase in airway
lumen tapering (P = 0.002) all remain
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independently signiﬁcantly associated with
daughter branches missing or not missing
after adjusting for confounding variables in
a multivariable logistic regression model
(see Table E4).
Further analysis (see Table E5) in a
subgroup of participants (n = 494) in which
PRM measurements were obtained showed
in a multivariable regression model after
adjusting for confounding variables that TAC
was signiﬁcantly and negatively associated
with PRM-fSAD measurements (P = 0.0002),
but not PRM-emphysema (P = 0.53).
Was TAC the Dominant Contributor to
Pulmonary Function?
Table 2 shows the results of multivariable
regression analysis for pulmonary function
measurements that included all CT
measurements in the same model in all
participants adjusted for cofounding
variables. Among all imaging measures
investigated, the standardized beta
coefﬁcients (b) indicated that TAC
(b = 0.18; P, 0.0001) had the greatest relative
inﬂuence on FEV1, followed by LAA950
(b =20.14; P, 0.0001) and inner area
(b = 0.06; P = 0.02). TAC (b = 0.40;
P, 0.0001) also had the greatest relative
inﬂuence on FEV1/FVC, followed by
LAA950 (b =20.20; P, 0.0001), LAA856
(b =20.12; P, 0.0001), and inner
area (b = 0.08; P = 0.009). For RV/TLC,
Pi10 (b =20.13; P, 0.0001) and TAC
(b =20.12; P = 0.0008) had the greatest
relative inﬂuence followed by LAA856
(b = 0.10; P = 0.003). For BDR, signiﬁcant
associations were shown for both TAC
(b =20.27; P, 0.0001) and LAA856
(b = 0.12; P = 0.0004), although the
TAC had the greatest relative inﬂuence.
The relative inﬂuence of TAC was also
greater than all other imaging measures on
FEV1, FEV1/FVC, and BDR when the
GOLD I and GOLD II COPD groups
were investigated separately (see Tables
E6–E9).
Was TAC Associated with
Longitudinal Lung Function
Decline?
Table 3 shows multivariable linear
mixed effects regression models for
longitudinal FEV1 and FEV1/FVC
decline in all participants that included
CT TAC and LAA950 in the same
model and was adjusted for baseline
cofounding variables (age, sex, BMI,
race, smoking status, FEV1); the
expanded table with all parameters
is shown in Table E10. Over an
approximately 6-year time frame,
TAC was signiﬁcantly associated with
longitudinal decline in FEV1 (P = 0.02)
and FEV1/FVC (P = 0.01) independent
of LAA950 and baseline FEV1.
Table 1. Subject Demographics, Pulmonary Function, and Imaging Measurements
Parameter Never-Smoker (n = 286) At-Risk (n = 298) GOLD I (n = 361) GOLD II (n = 239)
Subject demographics
Age, yr 66 (10) 66 (9) 68 (10)* 66 (10)
Female sex, n (%) 136 (48) 131 (44) 124 (34)*† 100 (42)
White, n (%) 266 (93) 283 (95) 347 (96) 223 (93)
Pack-years, yr 0 (0) 21 (24)† 18 (23)† 26 (26)*†‡
BMI, kg/m2 27 (5) 28 (5) 27 (4) 28 (6)
Current-smoker, n (%) — 64 (21) 52 (14)* 61 (26)
History of asthma, n (%) 21 (7) 30 (10) 66 (18)*† 86 (36)*†‡
History of tuberculosis, n (%) 3 (1) 0 (0) 5 (1) 5 (2)*
History of HDHTDM, n (%) 97 (34) 106 (36) 131 (36) 115 (48)*†‡
History of bronchiectasis, n (%) 54 (19) 48 (16) 75 (21) 48 (20)
Pulmonary function
FEV1, %pred 106 (15) 103 (14)
† 96 (12)*† 69 (8)*†‡
FEV1/FVC, % 78 (5) 77 (5) 64 (5)*
† 59 (8)*†‡
RV/TLC, % 37 (8) 37 (7) 40 (9)*† 46 (9)*†‡
DLCO, %pred 115 (23) 113 (22) 109 (23)
† 94 (24)*†‡
BDR FEV1, % 4 (30) 3 (31) 7 (45)*
† 10 (49)*†‡
Imaging
LAA856, % 21 (17) 18 (15) 29 (16)*
† 31 (19)*†
LAA950, % 3 (3) 3 (3) 5 (5)*
† 5 (5)*†
TAC, n 221 (73) 217 (68) 190 (66)*† 152 (53)*†‡
Pi10, mm 3.9 (0.1) 3.9 (0.1) 3.9 (0.1) 3.9 (0.1)
Inner area, mm2 12.1 (4.6) 11.8 (3.2) 10.8 (3.1)*† 9.5 (2.6)*†‡
PRM fSAD, %x 12 (13) 10 (11) 18 (15)*† 21 (17)*†
PRM Emph, %x 0.02 (0.06) 0.02 (0.03) 0.17 (0.62) 0.55 (2.24)*†‡
Definition of abbreviations: %pred = percent predicted; BDR = bronchodilator response; BMI = body mass index; Emph = emphysema; fSAD = functional
small airway disease; GOLD =Global Initiative for Chronic Obstructive Lung Disease; HDHTDM= heart disease, systemic hypertension, or diabetes
mellitus; LAA856 = low-attenuation area of the lung with attenuation values below 2856 Hounsfield units on full-expiration computed tomography;
LAA950 = low-attenuation area of the lung with attenuation values below 2950 Hounsfield units on full-inspiration computed tomography; Pi10 = the
square root of the airway wall area for a theoretical airway with 10-mm internal perimeter; PRM = parametric response map; RV = residual volume;
TAC = total airway count; TLC = total lung capacity.
Data are shown as mean (SD) unless otherwise specified.
*Significantly different from at-risk (P, 0.05).
†Significantly different from never-smoker (P, 0.05).
‡Significantly different from GOLD I (P, 0.05).
xn = 140, n = 103, n = 149, and n = 102 in never-smokers, at-risk, GOLD I, and GOLD II, respectively.
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Discussion
The development of effective therapies for
COPD requires a thorough understanding
of the disease pathogenesis. With increasing
evidence pointing to small airway
destruction as the precursor to emphysema
development (3), sensitive tools are needed
that can identify small airway disease in the
earliest stages. Although reduction in the
number of terminal bronchioles measured
using micro-CT has been shown to occur
early in the disease course (3), few studies
have investigated the TAC in vivo using CT.
Diaz and colleagues (17) demonstrated that
the total number of CT airways correlates
with emphysema extent, pulmonary
function measurements, and dyspnea in
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Figure 2. Computed tomography airway count by generation and airway lumen diameter. The three-dimensional reconstruction of the segmented airway
tree generated by VIDA Diagnostics Inc. for never-smokers and participants at risk and with Global Initiative for Chronic Obstructive Lung Disease (GOLD) I
and GOLD II chronic obstructive pulmonary disease (A). The plot summary data show airway counts for airways color coded by airway generation (B)
and by various sizes divided into discrete bins (C). Error bars represent the SD of the airway counts for all participants. *Significantly different from never-
smoker. †Significantly different from at-risk. ‡Significantly different from GOLD I. CT = computed tomography.
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COPD. However, the cohort of participants
investigated by Diaz and colleagues (17)
had severe emphysema and therefore it
is unknown whether reduced CT airway
count occurred before emphysema
development.
To our knowledge, there have been no
studies investigating CT airway count in a
population-based sample of participants at
risk and with milder COPD. Our ﬁndings
extend important early observations (17),
and here in this population-based study we
report the following: 1) compared with
at-risk participants, TAC was reduced by
17% in mild (GOLD I) COPD, independent
of emphysema; 2) missing airways were
spatially related to airway luminal
narrowing and tapering, and wall thinning
of parent airway segments; 3) among all CT
measurements investigated, TAC had the
greatest relative inﬂuence on pulmonary
function; and 4) reduced TAC was
independently associated with longitudinal
lung function decline over a 6-year time
frame. Importantly, these ﬁndings also
extend early observations by demonstrating
the feasibility and applicability of this
analysis by using CT images acquired with
standard CT image acquisition protocols
across varying CT platforms and at various
sites using commercially available software.
In comparison with other large COPD
cohort studies that recruit from outpatient
clinics of large medical centers, such as
COPDGene (Genetic Epidemiology of
COPD) (18), ECLIPSE (Evaluation of
COPD Longitudinally to Identify Predictive
Surrogate End-points) (19), and
SPIROMICS (Subpopulations and
Intermediate Outcomes in COPD Study)
(20), participants recruited from
population-based studies like CanCOLD
have earlier and milder forms of COPD
and, consequently, lower levels of
emphysema. In these participants with low
levels of emphysema, we demonstrated
that the number of CT airways was
reduced in GOLD I and GOLD II COPD
compared with never-smokers and at-risk
participants in the fourth generation and
beyond. Furthermore, we demonstrated
that various sized airways were reduced in
GOLD I and GOLD II COPD, except for
airways less than 2.50 mm in diameter.
These ﬁndings that airway counts are
reduced in GOLD I and GOLD II COPD
are in accordance with the ﬁndings by
McDonough and colleagues (3). Although
McDonough and colleagues (3) showed
that the number of CT airways
2.0–2.5 mm in diameter was reduced in
COPD, the airways in this study were
manually counted, whereas the current
investigation used commercially available
airway segmentation software. Because
airways of this size are approaching the CT
resolutions limits, it is likely that the
automated software does not perform as
well as an experienced observed and
therefore the software may not have counted
enough airways 2.0–2.5 mm in diameter to
reach statistical signiﬁcance between the
groups. However, it must be noted that
manual airway segmentation and airway
counting requires a signiﬁcant amount of
time therefore limiting its applicability in
routine COPD management. Furthermore,
we note that other validated, automated CT
software for airway analysis also reports
airway segmentation up to the 14th
generation, supporting the notion that the
CT smaller airways can be reproducibly
evaluated (21, 22).
Importantly, our ﬁnding that TAC,
which includes all measured airways, was
reduced even in mild (GOLD I) COPD
participants using commercially available
software indicate that this analysis could
be feasible and widely applicable using
routine CT image acquisition protocols
across various sites and CT platforms.
Interestingly, the ﬁnding that airway counts
were reduced in airways of various sizes, and
not only the smaller airways, suggests
narrowing, obstruction, and/or destruction
occurs more uniformly throughout the
airway tree. Moreover, the ﬁnding that TAC
was reduced in GOLD I and GOLD II
COPD independent of emphysema suggests
that emphysematous destruction is not the
only factor driving the reduction in airway
count.
We next investigated other factors that
may be driving the reduction in CT airway
count and found that participants with
parent airway segments with missing
daughter branches had signiﬁcantly reduced
lumen diameters, thinner airway walls, and
signiﬁcantly more tapered airways than
participants with airways not missing a
daughter branch. These ﬁndings suggest
that airway luminal narrowing and wall
thinning make it difﬁcult to resolve distal,
daughter airways using CT. This is
supported by Smith and colleagues (9)
ﬁndings that CT airway walls are thinner in
COPD compared with control subjects.
Although we cannot determine in the
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Figure 3. Computed tomography (CT) airway count unadjusted and adjusted by low-attenuation
areas of the lung below2950 Hounsfield units (LAA950) for never-smokers and participants at risk and
with Global Initiative for Chronic Obstructive Lung Disease (GOLD) I and GOLD II chronic obstructive
pulmonary disease. The total airway count was significantly reduced in GOLD I and GOLD II
compared with never-smokers (P, 0.0001) and at-risk (P, 0.0001) in both LAA950 adjusted and
unadjusted models. Also adjusted by age; sex; race; pack-years; smoking status; body mass index;
history of asthma; history of tuberculosis; history of history of heart disease, systemic hypertension,
or diabetes mellitus; bronchiectasis, CT air volume; and CT model. The boxes are centered on
the mean, and the whiskers represent the 95% confidence intervals. *Significantly different (,0.05).
NS = never-smoker; TAC = total airway count.
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current study exactly what caused airways
to appear as missing in CT, whether it be
airway luminal narrowing caused by
excessive bronchoconstriction, mucus
occlusion, or airway wall thinning due to
degradation of the walls, our ﬁndings
suggest it is at least in part related to
structural abnormalities in the airways.
Although only a small subset of the
participants were investigated, this notion
was also supported by the ﬁnding that TAC
was signiﬁcantly associated with PRM
fSAD measurements, independent of
emphysema.
TAC was also shown to have the
greatest relative inﬂuence on pulmonary
function measurements (FEV1, FEV1/FVC,
RV/TLC, and BDR) among all the CT
measurements investigated. CT airway
count therefore provided unique
information related to pulmonary function
independent of the extent of emphysema,
the extent of expiratory gas trapping,
remodeling of the airway walls, and
segmental airway luminal narrowing.
Furthermore, the ﬁnding that TAC was
signiﬁcantly associated with pulmonary
function independent of segmental airway
luminal narrowing suggests that TAC
reﬂects luminal narrowing not only in
central airways, but also more distal
airways. We note that CT gas volume
and bronchiectasis were included as
confounding variables and therefore this
ﬁnding was not a direct result of more CT
airways visible due to great lung volumes or
more dilated airways. We also note that
our ﬁnding that TAC was signiﬁcantly
associated with airﬂow limitation in
never-smokers (see online supplement)
was surprising and suggests that lung
development may play a role in reduced
airway count. Diaz and colleagues (23)
also provided evidence that CT airway
dimension measurements are related to
airﬂow limitation in never-smokers, which
supports this notion. Whether individuals
with reduced TAC may be more susceptible
to the development of COPD (i.e., they may
have different lung function trajectories
[24]) is an important question, and
although it is beyond the scope of this study
to investigate, it is one that deserves further
investigation.
Finally, we showed that participants
with reduced TAC had accelerated lung
function decline over the 6-year time
frame, irrespective of baseline FEV1,
emphysema, and other confounding
variables. Initiating treatment in patients
with or at risk of COPD with early airway-
related disease changes before emphysema
develops may hold the greatest promise for
slowing disease progression. Our ﬁndings
indicate that CT airway count may serve as
an imaging biomarker reﬂecting airway-
related structural changes. Therefore CT
TAC may be useful to stratify patients with
reduced TAC into clinical trials to enrich
clinical trials with participants with early
evidence of airway abnormalities or to
serve as a sensitive intermediate endpoint
to evaluate the impact of novel COPD
treatment. However, evaluating CT TAC
longitudinally to determine if reduced
TAC over time is associated with clinical
outcomes, and pathologic validation, is
required before the potential of this
measurement in clinical trials can be
realized. Furthermore, an unmet need
in COPD patient management is
identifying patients at the greatest risk
of accelerated disease progression. Our
ﬁndings indicate that patients with
reduced CT TAC have accelerated lung
function decline. Although there are
currently limited treatment options for
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Figure 4. Subsegmental airway lumen diameter and airway tapering and airway wall area percent
measurements for participants with subsegmental airways either not missing or missing their sub-
subsegmental daughter branches. The three-dimensional reconstruction of the segmented airway
tree with the path to RB1 highlighted in green along with the two-dimensional airway path from the
trachea to the sub-subsegmental daughter branch of RB1 (RB1ai) for a participant with their sub-
subsegmental daughter branch not missing (A) or missing (B). The subsegmental RB1 daughter branch
(RB1a) distal to the missing airway is highlighted in yellow, and the airway inner diameter measurements
are shown below. For all subsegmental airways evaluated, the inner diameter, airway wall area, and inner
diameter tapering measurements were significantly reduced for all participants with a daughter branch
missing (P, 0.0001) compared with those with a daughter branch not missing (C). The box extends from
the 25th to 75th percentiles, the middle line is the median, and the whiskers represent the 5–95
percentiles. Significance of difference (P) was determined using Mann-Whitney t test (P, 0.05). RB1 =
apical segment of the right upper lobe bronchus; RMB= right main bronchus; RUL = right upper lobe.
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patients with COPD, a measurement
that can indicate which patients are at
increased risk of accelerated disease
progression would enable clinicians to
more carefully monitor those patients
over time.
This study has limitations that deserve
mention. We must note that histologic
validation of TAC in explanted lung tissue
was beyond the scope of this study, but
is critical in understanding the factors
dominating TAC reduction in patients with
varying stages of COPD. Although
pathology validation is complex, using a
novel approach that links CT to micro-CT
and histology in exactly the same ex vivo
samples of tissue (25) will enable the
investigation of whether small airways
disease in the lung’s quiet zone
(preterminal and terminal bronchioles) is
reﬂected in the more central airways as
measured by TAC. We also acknowledge
that the longitudinal data collection for this
study is still ongoing, and therefore the
number of participants with complete
longitudinal data (n = 638) was limited
as was the longitudinal time frame of
approximately 6 years. Another important
limitation is the fact that CT was acquired
at nine centers that used a variety of CT
models by different manufacturers, and we
did not use a phantom to standardize CT
measurements at each center. Although we
adjusted for CT model in our multivariable
linear regression models, we acknowledge
this is a limitation. We note that our image
acquisition protocol was based on the
image acquisition protocol used in
the COPDGene cohort study (18).
Furthermore, we acknowledge efforts of
the Quantitative Imaging Biomarkers
Alliance Lung Density Committee to
conduct phantom studies to assess the
measurement variation attributed to
different CT manufacturers (26). Reducing
this nonbiologic CT measurement
variability will allow for more reproducible
measurements, which is clearly important
for future multicenter studies.
In conclusion, although pathologic
validation is needed these ﬁndings suggest
CT TAC may reﬂect the same airway-
related disease changes observed in the
small airways, the “quiet” zone of the lung
(27), that signiﬁcant reduction in TAC
occurs in very mild COPD, and that
reduced TAC predicts more rapid
lung-function decline. Taken together,
these ﬁndings indicate that early
intervention may be required for optimal
disease modiﬁcation. n
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Table 2. Multivariable Regression Models for Pulmonary Function Measurements with
All Imaging Measurements Included in the Same Model in All Participants
Standardized
Estimate SE
Variance Inﬂation
Factor P Value
FEV1*, L
LAA856 20.04 0.0009 1.61 0.08
LAA950 20.14 0.004 1.67 ,0.0001
TAC 0.18 0.0002 1.89 ,0.0001
Pi10 0.007 0.11 1.36 0.72
Inner area 0.06 0.005 2.01 0.02
FEV1/FVC*
LAA856 20.12 0.01 1.61 ,0.0001
LAA950 20.20 0.06 1.67 ,0.0001
TAC 0.40 0.004 1.89 ,0.0001
Pi10 20.02 1.69 1.36 0.48
Inner area 0.08 0.08 2.01 0.009
RV/TLC*
LAA856 0.10 0.0002 1.60 0.003
LAA950 0.04 0.0007 1.69 0.24
TAC 20.12 0.00004 1.87 0.0008
Pi10 20.13 0.02 1.37 ,0.0001
Inner area 20.05 0.0009 1.99 0.16
BDR FEV1*, %
LAA856 0.12 0.0002 1.61 0.0004
LAA950 0.04 0.0006 1.67 0.22
TAC 20.27 0.00004 1.89 ,0.0001
Pi10 20.002 0.02 1.36 0.95
Inner area 20.06 0.008 2.01 0.13
Definition of abbreviations: BDR=bronchodilator response; CT= computed tomography; LAA856 =
low-attenuation area of the lung with attenuation values below 2856 Hounsfield units on full-expiration CT;
LAA950 = low-attenuation area of the lung with attenuation values below 2950 Hounsfield units on
full-inspiration CT; Pi10 = the square root of the airway wall area for a theoretical airway with 10-mm internal
perimeter; RV= residual volume; TAC= total airway count; TLC= total lung capacity.
*Adjusted by age; sex; race; pack-years; smoking status; body mass index; history of asthma; history
of tuberculosis; history of heart disease, systemic hypertension, or diabetes mellitus; bronchiectasis;
CT air volume; and CT model.
Table 3. Mixed Effects Multivariable Regression Models for Longitudinal
Lung-Function Decline
Interactions Estimate (95% CI) SE P Value
Model 1: FEV1*, ml
FEV13 time 217.53 (220.74 to 214.32) 1.64 ,0.0001
TAC3 time 0.04 (0.01 to 0.08) 0.02 0.02
LAA9503 time 20.86 (21.42 to 20.29) 0.29 0.003
Model 2: FEV1/FVC*, %
FEV13 time 20.008 (20.08 to 0.06) 0.03 0.81
TAC3 time 0.0009 (0.0002 to 20.002) 0.0004 0.01
LAA9503 time 20.02 (20.03 to 20.007) 0.006 0.002
Definition of abbreviations: CI = confidence interval; LAA950 = low-attenuation area of the lung with
attenuation values below 2950 Hounsfield units on full-inspiration computed tomography; TAC =
total airway count.
*Also included in the model: time and baseline age (yr), sex (female), body mass index (kg/m2), white,
smoking status, FEV1 (L), TAC (n), and LAA950 (%).
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